Related Experiment Video
Updated: Jul 2, 2026

Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Role of Postoperative Radiation Therapy After Radical Cystectomy for Bladder Cancer: A Systematic Review and
Rafael Lara Nohmi1, Fabricia Cardoso Marques2, Heloisa Carneiro Brito3
1Universidade de São Paulo (USP), São Paulo, São Paulo, Brazil.
Purpose:
Radical cystectomy with neoadjuvant cisplatin-based chemotherapy is the standard of care for muscle-invasive bladder cancer (MIBC). However, recurrence remains common. Postoperative radiation therapy (PORT) has been explored to improve locoregional control and survival, but evidence remains inconclusive. This systematic review and meta-analysis assessed the role of PORT in MIBC.
Methods And Materials:
PubMed, Embase, and Cochrane were searched through March 2025 (CRD42025632052). Eligible studies included randomized controlled trials (RCTs), prospective nonrandomized studies, and comparative observational cohorts of patients with MIBC undergoing radical cystectomy, with or without PORT. Prospective single-arm studies of PORT were included for safety outcomes. Primary outcomes were overall survival (OS) and recurrence-free survival (RFS); secondary outcomes included locoregional recurrence (LRR) and treatment-related toxicities. Random-effects models were used.
Results:
Fifteen studies (5 RCTs, 2 prospective nonrandomized, and 8 retrospective cohorts) were included. A total of 19,033 patients (PORT, 1157) were included in the comparative analysis. PORT was associated with improved OS (hazard ratio, 0.84; 95% CI, 0.71-0.98; P = .026), although these results were not maintained in urothelial-only analysis. LRR was markedly reduced (risk ratio, 0.31; 95% CI, 0.15-0.65; P = .002), a finding maintained in urothelial-only and RCT-only analyses. No RFS benefit was observed in the primary analysis, but sensitivity, urothelial-only, and RCT-only analyses demonstrated significant improvements. Grade ≥3 acute gastrointestinal and genitourinary toxicities occurred in 3.3% and 1.8% of patients, respectively; late toxicities in 4.3% and 0.62%.
Conclusions:
PORT reduced LRR across all analyses, improved OS in the overall and RCT-only analysis, and showed RFS benefits in sensitivity, urothelial-only, and RCT-only analyses. PORT may benefit selected high-risk patients, and its integration with contemporary radiation and systemic therapies warrants further prospective evaluation.
Related Concept Videos
Imaging Studies VI: Voiding Cystourethrography and Cystography
Urologic Endoscopic Procedure: Cystoscopic Examination